1. ZHAW digitalcollection
  2. Angewandte Psychologie
  3. Publikationen
  4. Publikationen Angewandte Psychologie
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHengartner, Michael Pascal-
dc.contributor.authorPlöderl, Martin-
dc.date.accessioned2021-03-26T15:38:05Z-
dc.date.available2021-03-26T15:38:05Z-
dc.date.issued2021-
dc.identifier.issn2515-446Xde_CH
dc.identifier.issn2515-4478de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/22199-
dc.description.abstractThe efficacy of antidepressants in the acute treatment of moderate-to-severe depression remains a controversial issue. The minimal important difference (MID) is relevant to judge the clinical significance of treatment effects. In this analysis paper, we discuss estimates of the MID for common depression outcome measures.For the Hamilton Depression Rating Scale 17-item Version (HDRS-17), according to both anchor-based and distribution-based approaches, MID estimates range from 3 to 8 points, and the most accurate values are likely between 3 and 5 points. For the 6-item version (HDRS-6), MID estimates range between 2 and 4 points. For both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Beck Depression Inventory II (BDI-II), MID estimates range between 3 and 9 points, with estimates of 3-6 points likely being the most accurate. Quality of life appears to be more important to patients than core depression symptoms. We thus also evaluated the Short-Form 36 (SF-36) mental component score, a popular mental-health-related quality of life measure. Its MID estimate is likely about 5 points. By contrast, the average treatment effects of antidepressants on the HDRS-17, HDRS-6, MADRS, BDI-II and SF-36 are 2 points, 1.5 points, 3 points, 2 points and 3-5 points, respectively.In conclusion, the efficacy of antidepressants in the acute treatment of moderate-to-severe depression consistently fails to exceed the lower bound of the MID estimates for common depression outcome measures. The clinical significance of antidepressants thus remains uncertain and we call for more research on quality of life measures, which are the patients' most valued outcome domains.de_CH
dc.language.isoende_CH
dc.publisherBMJ Publishing Groupde_CH
dc.relation.ispartofBMJ Evidence-Based Medicinede_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectClinical decision-makingde_CH
dc.subjectEvidence-based practicede_CH
dc.subjectGeneral practicede_CH
dc.subjectHealth care qualityde_CH
dc.subjectHealth care accessde_CH
dc.subjectHealth care evaluationde_CH
dc.subject.ddc615: Pharmakologie und Therapeutikde_CH
dc.titleEstimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depressionde_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementAngewandte Psychologiede_CH
zhaw.organisationalunitPsychologisches Institut (PI)de_CH
dc.identifier.doi10.1136/bmjebm-2020-111600de_CH
dc.identifier.pmid33593736de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
zhaw.webfeedKlinische Psychologiede_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen Angewandte Psychologie

Files in This Item:
There are no files associated with this item.
Show simple item record
Hengartner, M. P., & Plöderl, M. (2021). Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evidence-Based Medicine. https://doi.org/10.1136/bmjebm-2020-111600
Hengartner, M.P. and Plöderl, M. (2021) ‘Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression’, BMJ Evidence-Based Medicine [Preprint]. Available at: https://doi.org/10.1136/bmjebm-2020-111600.
M. P. Hengartner and M. Plöderl, “Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression,” BMJ Evidence-Based Medicine, 2021, doi: 10.1136/bmjebm-2020-111600.
HENGARTNER, Michael Pascal und Martin PLÖDERL, 2021. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evidence-Based Medicine. 2021. DOI 10.1136/bmjebm-2020-111600
Hengartner, Michael Pascal, and Martin Plöderl. 2021. “Estimates of the Minimal Important Difference to Evaluate the Clinical Significance of Antidepressants in the Acute Treatment of Moderate-to-Severe Depression.” BMJ Evidence-Based Medicine. https://doi.org/10.1136/bmjebm-2020-111600.
Hengartner, Michael Pascal, and Martin Plöderl. “Estimates of the Minimal Important Difference to Evaluate the Clinical Significance of Antidepressants in the Acute Treatment of Moderate-to-Severe Depression.” BMJ Evidence-Based Medicine, 2021, https://doi.org/10.1136/bmjebm-2020-111600.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.